Cargando…
New Insights into Iron Deficiency Anemia in Children: A Practical Review
Iron deficiency anemia (IDA) is the most frequent hematological disorder in children, with an incidence in industrialized countries of 20.1% between 0 and 4 years of age and 5.9% between 5 and 14 years (39 and 48.1% in developing countries). Although IDA has been recognized for a long time, there ar...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029079/ https://www.ncbi.nlm.nih.gov/pubmed/35448476 http://dx.doi.org/10.3390/metabo12040289 |
_version_ | 1784691787679399936 |
---|---|
author | Moscheo, Carla Licciardello, Maria Samperi, Piera La Spina, Milena Di Cataldo, Andrea Russo, Giovanna |
author_facet | Moscheo, Carla Licciardello, Maria Samperi, Piera La Spina, Milena Di Cataldo, Andrea Russo, Giovanna |
author_sort | Moscheo, Carla |
collection | PubMed |
description | Iron deficiency anemia (IDA) is the most frequent hematological disorder in children, with an incidence in industrialized countries of 20.1% between 0 and 4 years of age and 5.9% between 5 and 14 years (39 and 48.1% in developing countries). Although IDA has been recognized for a long time, there are still uncovered issues and room for improving the management of this condition. New frontiers regarding its diagnosis and therapeutic options emerge every day; recently, innovative formulations of iron have been launched, both for oral and parenteral administration, with the aim of offering treatment schedules with higher efficacy and lower toxicity. As a matter of fact, glycinate and liposomal preparations, while maintaining a satisfying efficacy profile, have significantly fewer side effects, in comparison to the traditional elemental iron salts; parenteral iron, usually considered a second-choice therapy reserved to selected cases, may evolve further, as a consequence of the production of molecules with an interesting clinical profile such as ferrocarboxymaltose, which is already available for adolescents aged >14 years. The present article reports the clinically relevant latest insights regarding IDA in children and offers a practical guide to help pediatricians, particularly to choose the most appropriate prevention and therapy strategies. |
format | Online Article Text |
id | pubmed-9029079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90290792022-04-23 New Insights into Iron Deficiency Anemia in Children: A Practical Review Moscheo, Carla Licciardello, Maria Samperi, Piera La Spina, Milena Di Cataldo, Andrea Russo, Giovanna Metabolites Review Iron deficiency anemia (IDA) is the most frequent hematological disorder in children, with an incidence in industrialized countries of 20.1% between 0 and 4 years of age and 5.9% between 5 and 14 years (39 and 48.1% in developing countries). Although IDA has been recognized for a long time, there are still uncovered issues and room for improving the management of this condition. New frontiers regarding its diagnosis and therapeutic options emerge every day; recently, innovative formulations of iron have been launched, both for oral and parenteral administration, with the aim of offering treatment schedules with higher efficacy and lower toxicity. As a matter of fact, glycinate and liposomal preparations, while maintaining a satisfying efficacy profile, have significantly fewer side effects, in comparison to the traditional elemental iron salts; parenteral iron, usually considered a second-choice therapy reserved to selected cases, may evolve further, as a consequence of the production of molecules with an interesting clinical profile such as ferrocarboxymaltose, which is already available for adolescents aged >14 years. The present article reports the clinically relevant latest insights regarding IDA in children and offers a practical guide to help pediatricians, particularly to choose the most appropriate prevention and therapy strategies. MDPI 2022-03-25 /pmc/articles/PMC9029079/ /pubmed/35448476 http://dx.doi.org/10.3390/metabo12040289 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Moscheo, Carla Licciardello, Maria Samperi, Piera La Spina, Milena Di Cataldo, Andrea Russo, Giovanna New Insights into Iron Deficiency Anemia in Children: A Practical Review |
title | New Insights into Iron Deficiency Anemia in Children: A Practical Review |
title_full | New Insights into Iron Deficiency Anemia in Children: A Practical Review |
title_fullStr | New Insights into Iron Deficiency Anemia in Children: A Practical Review |
title_full_unstemmed | New Insights into Iron Deficiency Anemia in Children: A Practical Review |
title_short | New Insights into Iron Deficiency Anemia in Children: A Practical Review |
title_sort | new insights into iron deficiency anemia in children: a practical review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029079/ https://www.ncbi.nlm.nih.gov/pubmed/35448476 http://dx.doi.org/10.3390/metabo12040289 |
work_keys_str_mv | AT moscheocarla newinsightsintoirondeficiencyanemiainchildrenapracticalreview AT licciardellomaria newinsightsintoirondeficiencyanemiainchildrenapracticalreview AT samperipiera newinsightsintoirondeficiencyanemiainchildrenapracticalreview AT laspinamilena newinsightsintoirondeficiencyanemiainchildrenapracticalreview AT dicataldoandrea newinsightsintoirondeficiencyanemiainchildrenapracticalreview AT russogiovanna newinsightsintoirondeficiencyanemiainchildrenapracticalreview |